Research programme: anthrax vaccine (third generation) - Altimmune

Drug Profile

Research programme: anthrax vaccine (third generation) - Altimmune

Alternative Names: Lyophilized recombinant protective antigen anthrax vaccine; Lyophilized rPA anthrax vaccine; SparVax-L

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avecia
  • Developer Altimmune
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 04 May 2017 PharmAthene merged with Altimmune and the combined entity was renamed as Altimmune
  • 14 Mar 2017 PharmAthene plans a phase II bridging study for Anthrax, in the second half of 2017 (PharmAthene 10-K, March 2017)
  • 15 Feb 2017 PharmAthene has patent protection for anthrax vaccine formulation and uses thereof in Europe (PharmAthene 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top